Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.15
0.000.00%
At close: -
$2.16
0.010.47%
After Hours: 5:29 PM EDT
Comments
Loading...
MaxCyte Analyst Ratings and Price Targets | NASDAQ:MXCT | Benzinga
MaxCyte Inc has a consensus price target of $8.75 based on the ratings of 4 analysts. The high is $11 issued by Stephens & Co. on April 23, 2024. The low is $7 issued by Craig-Hallum on November 29, 2023. The 3 most-recent analyst ratings were released by Stifel, Stephens & Co., and Stephens & Co. on March 12, 2025, April 23, 2024, and March 13, 2024, respectively. With an average price target of $10.33 between Stifel, Stephens & Co., and Stephens & Co., there's an implied 378.40% upside for MaxCyte Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Stephens & Co.
BTIG
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for MaxCyte
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/12/2025 | Buy Now | 316.67% | Stifel | Daniel Arias78% | $11 → $9 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | 409.26% | Stephens & Co. | Jacob Johnson60% | $11 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2024 | Buy Now | 409.26% | Stephens & Co. | Jacob Johnson60% | $11 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2024 | Buy Now | 270.37% | BTIG | Mark Massaro71% | $10 → $8 | Maintains | Buy | Get Alert |
| 11/29/2023 | Buy Now | 224.07% | Craig-Hallum | Matt Hewitt55% | → $7 | Initiates | → Buy | Get Alert |
| 10/05/2023 | Buy Now | 455.56% | Stephens & Co. | Jacob Johnson60% | → $12 | Reiterates | Overweight → Overweight | Get Alert |
| 03/28/2023 | Buy Now | 455.56% | Stephens & Co. | Jacob Johnson60% | → $12 | Reiterates | → Overweight | Get Alert |
| 08/15/2022 | Buy Now | 409.26% | BTIG | Mark Massaro71% | $10 → $11 | Maintains | Buy | Get Alert |
FAQ
What is the target price for MaxCyte (MXCT) stock?
The latest price target for MaxCyte (NASDAQ:MXCT) was reported by Stifel on March 12, 2025. The analyst firm set a price target for $9.00 expecting MXCT to rise to within 12 months (a possible 316.67% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MaxCyte (MXCT)?
The latest analyst rating for MaxCyte (NASDAQ:MXCT) was provided by Stifel, and MaxCyte maintained their buy rating.
When was the last upgrade for MaxCyte (MXCT)?
There is no last upgrade for MaxCyte
When was the last downgrade for MaxCyte (MXCT)?
There is no last downgrade for MaxCyte.
When is the next analyst rating going to be posted or updated for MaxCyte (MXCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MaxCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MaxCyte was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.
Is the Analyst Rating MaxCyte (MXCT) correct?
While ratings are subjective and will change, the latest MaxCyte (MXCT) rating was a maintained with a price target of $11.00 to $9.00. The current price MaxCyte (MXCT) is trading at is $2.16, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
